News-Medical.Net on MSN
Novel immunotherapy targeting pancreatic cancer shows promising results in phase 1/2 trial
A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...
Furthermore, a near-doubling of 12-month survival was also achieved with the elraglusib regimen vs GnP alone (44.4% vs 22.3%) ...
A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...
The two newest appointees are obstetrician-gynecologists who at times have challenged broad medical consensus.
News-Medical.Net on MSN
Novel antibody shows promise in overcoming resistance to cancer immunotherapy
According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback